Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Model-informed precision dosing of tamoxifen in hormone receptor-positive breast cancer
NL-OMON53836Not yet recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoint: Main study parameter. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53836.